COVID-19 related pancreatic cancer surveillance disruptions amongst high-risk individuals
Pancreatology . 2021 Apr 20;S1424-3903(21)00144-7. doi: 10.1016/j.pan.2021.04.005. Online ahead of print.
Bryson W Katona, Nadim Mahmud, Mohamad Dbouk, Nuzhat Ahmad, Ankit Chhoda, Beth Dudley, Umar Hayat, Richard S Kwon, Linda S Lee, Anil K Rustgi, Chinedu Ukaegbu, Lisa Vasquez, Sarah Volk, Randall E Brand, Marcia I Canto, Amitabh Chak, James J Farrell, Fay Kastrinos, Elena M Stoffel, Sapna Syngal, Michael Goggins
Background: COVID-19 pandemic-related disruptions to EUS-based pancreatic cancer surveillance in high-risk individuals remain uncertain.
Methods: Analysis of enrolled participants in the CAPS5 Study, a prospective multicenter study of pancreatic cancer surveillance in high-risk individuals.
Results: Amongst 693 enrolled high-risk individuals under active surveillance, 108 (16%) had an EUS scheduled during the COVID-19 pandemic-related shutdown (median length of 78 days) in the spring of 2020, with 97% of these procedures being canceled. Of these canceled surveillance EUSs, 83% were rescheduled in a median of 4.1 months, however 17% were not rescheduled after 6 months follow-up. Prior history of cancer was associated with increased likelihood of rescheduling. To date no pancreatic cancer has been diagnosed among those whose surveillance was delayed.
Conclusions: COVID-19 delayed pancreatic cancer surveillance with no adverse outcomes in efficiently rescheduled individuals. However, 1 in 6 high-risk individuals had not rescheduled surveillance, indicating the need for vigilance to ensure timely surveillance rescheduling.
Read Full Article Here: https://doi.org/10.1016/j.pan.2021.04.005